AtriCure, Inc. (ATRC) Stock Analysis and Metrics

AtriCure

NASDAQ: ATRC

$35.03 ▲ +2.03 (+6.14%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.70 Bn

P/E-370.37

P/S3.08

Div. Yield0.00

Total Debt (Qtr)61.00 Mn

Revenue Growth (1y) (Qtr)14.26

Add ratio to table…

About

AtriCure, Inc. is a leading innovator in surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post operative pain management. Atrial fibrillation affects over 59,000,000 people worldwide and is the most common sustained cardiac arrhythmia encountered in clinical practice. The company develops and sells devices that enable cardiac surgeons to perform ablation procedures, exclude the left atrial appendage, and manage pain following thoracic, cardiac, and amputation surgeries. Its products are used in both open heart and minimally invasive settings to treat arrhythmia, reduce stroke risk, and alleviate postoperative discomfort. By focusing on these therapeutic areas, AtriCure aims to improve patient outcomes and lower the burden of atrial fibrillation related complications on health care systems.

AtriCure generates revenue primarily from the sale of its medical devices to hospitals and surgical centers. The company sells ablation platforms, left atrial appendage exclusion systems, and cryo nerve block probes through a direct sales force in the United States, Germany, France, the United Kingdom, the Benelux region, Australia, and Canada, and through independent distributors in other international markets. Revenue is recognized when title transfers to the customer, typically upon shipment or delivery of the product. The disposable nature of probes and applicators creates a recurring revenue stream as physicians replenish supplies after each procedure. Additionally, the company places capital equipment such as radio frequency and cryogenic generators with customers and earns income from the sale of associated consumables.

AtriCure holds a leading position in the surgical atrial fibrillation market, particularly for the treatment of long standing persistent atrial fibrillation where few alternatives exist. The company’s main competitor in the cardiac surgery arena is Medtronic, which offers competing ablation and left atrial appendage devices. AtriCure differentiates itself through its portfolio of FDA cleared or approved products, including the Isolator Synergy ablation system, the EPi Sense system for hybrid therapy, and the AtriClip left atrial appendage exclusion system, which together provide physicians with tools for both epicardial and endocardial approaches. The firm also pioneered the use of cryo nerve block for post operative pain, giving it a unique niche in pain management. Over 750,000 patients have been treated with the AtriClip system worldwide, underscoring its adoption in left atrial appendage exclusion. Strong clinical evidence from trials such as CONVERGE and LAAOS III supports the safety and efficacy of its products, reinforcing confidence among surgeons and health care payors.

AtriCure serves hospitals, cardiac surgery centers, thoracic surgery facilities, and ambulatory surgical centers that perform procedures involving atrial fibrillation treatment, left atrial appendage exclusion, or post operative pain management. The company’s customers include academic medical centers, community hospitals, and private surgical groups across its commercial geographies. In addition, electrophysiologists and cardiothoracic surgeons rely on AtriCure’s technologies to deliver ablation therapy and manage postoperative discomfort. Specific customer names are not disclosed in the filing.

Investment Thesis

▲ Bull case

AtriCure’s BoxX NoAF clinical trial is enrolling patients at a pace far ahead of the original plan with approximately three hundred participants already enrolled in a nine hundred sixty patient study. This rapid enrollment suggests strong surgeon interest driven by the observed burden of postoperative atrial fibrillation and the lack of established prophylactic treatments. The company anticipates completing enrollment by the end of the current year nearly twelve months earlier than initially projected which would accelerate the timeline for data readout. Positive early signals from preliminary work indicate significant reductions in postoperative atrial fibrillation when using the EnCompass clamp combined with the AtriClip device which could translate into a meaningful clinical benefit and support a potential shift in standard of care for cardiac surgery patients.
The pain management franchise is experiencing accelerated growth with worldwide revenue up twenty eight% year over year driven primarily by the cryoSPHERE MAX probe which accounted for roughly seventy% of pain management sales in the quarter. Surgeons report substantial time savings and consistent clinical effectiveness leading to broader adoption in thoracic and sternotomy procedures. Early traction is also evident in the amputation setting where the cryoXT probe is beginning to gain use and generate positive feedback from new users. The underlying addressable market for post operative pain spans multiple surgical specialties and affects millions of patients providing a long runway for double digit growth that extends well beyond the current cardiac surgery base.
Open ablation revenue increased fifteen% year over year with the EnCompass clamp continuing to gain traction in both new and existing accounts across the United States and Europe. The recent inclusion of concomitant atrial fibrillation treatment as a quality metric by the Society of Thoracic Surgeons is expected to become effective in two thousand twenty seven and will likely drive higher ablation penetration rates from the current baseline of approximately thirty five% of eligible patients. This quality metric creates a structural tailwind that could push treatment rates toward eighty or ninety% over the next several years substantially expanding the addressable market for AtriCure’s ablation platforms. The ease of use and reproducible results associated with the EnCompass clamp position the company to capture a disproportionate share of this uplift.
AtriCure’s appendage management franchise benefits from deep clinical evidence generated through the LeAAPS and BoxX NoAF trials both of which specifically examine stroke reduction and postoperative atrial fibrillation prevention linked to left atrial appendage exclusion. This level of product specific data is currently unmatched by competitors who have not initiated comparable outcome studies giving AtriCure a potential moat in a market that is attracting new entrants such as Medtronic and the anticipated entry of Edwards. The strong surgeon preference for the FLEX Mini and PRO Mini devices reflected in their growing share of open appendage management revenue underscores the value of the mini form factor combined with proven performance. Continued investment in next generation appendage solutions and expanded geographic rollout in Europe China and Japan should sustain the franchise’s leadership position.
International direct markets including Europe Australia and Canada are delivering solid growth with constant currency increase of three point three% in the quarter supported by newer product launches such as the EnCompass clamp and the AtriClip FLEX Mini and PRO Mini which recently received CE Mark under EU MDR. Expansion into China and Japan is underway with recent regulatory clearances for AtriClip in China and expanded clearances for mini devices in Japan setting the stage for broader adoption in these high volume economies. The company expects international revenue to align with the overall corporate guidance of twelve to fourteen% growth for the full year indicating that current headwinds in the United Kingdom and Asia Pacific distributor channel are likely to be temporary. The underlying demand for minimally invasive and surgical atrial fibrillation solutions remains robust across geographies providing a diversified growth base.

AtriCure’s BoxX NoAF clinical trial is enrolling patients at a pace far ahead of the original plan with approximately three hundred participants already enrolled in a nine hundred sixty patient study. This rapid enrollment suggests strong surgeon interest driven by the observed burden of postoperative atrial fibrillation and the lack of established prophylactic treatments. The company anticipates completing enrollment by the end of the current year nearly twelve months earlier than initially projected which would accelerate the timeline for data readout. Positive early signals from preliminary work indicate significant reductions in postoperative atrial fibrillation when using the EnCompass clamp combined with the AtriClip device which could translate into a meaningful clinical benefit and support a potential shift in standard of care for cardiac surgery patients.
The pain management franchise is experiencing accelerated growth with worldwide revenue up twenty eight% year over year driven primarily by the cryoSPHERE MAX probe which accounted for roughly seventy% of pain management sales in the quarter. Surgeons report substantial time savings and consistent clinical effectiveness leading to broader adoption in thoracic and sternotomy procedures. Early traction is also evident in the amputation setting where the cryoXT probe is beginning to gain use and generate positive feedback from new users. The underlying addressable market for post operative pain spans multiple surgical specialties and affects millions of patients providing a long runway for double digit growth that extends well beyond the current cardiac surgery base.
Open ablation revenue increased fifteen% year over year with the EnCompass clamp continuing to gain traction in both new and existing accounts across the United States and Europe. The recent inclusion of concomitant atrial fibrillation treatment as a quality metric by the Society of Thoracic Surgeons is expected to become effective in two thousand twenty seven and will likely drive higher ablation penetration rates from the current baseline of approximately thirty five% of eligible patients. This quality metric creates a structural tailwind that could push treatment rates toward eighty or ninety% over the next several years substantially expanding the addressable market for AtriCure’s ablation platforms. The ease of use and reproducible results associated with the EnCompass clamp position the company to capture a disproportionate share of this uplift.
AtriCure’s appendage management franchise benefits from deep clinical evidence generated through the LeAAPS and BoxX NoAF trials both of which specifically examine stroke reduction and postoperative atrial fibrillation prevention linked to left atrial appendage exclusion. This level of product specific data is currently unmatched by competitors who have not initiated comparable outcome studies giving AtriCure a potential moat in a market that is attracting new entrants such as Medtronic and the anticipated entry of Edwards. The strong surgeon preference for the FLEX Mini and PRO Mini devices reflected in their growing share of open appendage management revenue underscores the value of the mini form factor combined with proven performance. Continued investment in next generation appendage solutions and expanded geographic rollout in Europe China and Japan should sustain the franchise’s leadership position.
International direct markets including Europe Australia and Canada are delivering solid growth with constant currency increase of three point three% in the quarter supported by newer product launches such as the EnCompass clamp and the AtriClip FLEX Mini and PRO Mini which recently received CE Mark under EU MDR. Expansion into China and Japan is underway with recent regulatory clearances for AtriClip in China and expanded clearances for mini devices in Japan setting the stage for broader adoption in these high volume economies. The company expects international revenue to align with the overall corporate guidance of twelve to fourteen% growth for the full year indicating that current headwinds in the United Kingdom and Asia Pacific distributor channel are likely to be temporary. The underlying demand for minimally invasive and surgical atrial fibrillation solutions remains robust across geographies providing a diversified growth base.

▼ Bear case

The minimally invasive ablation franchise showed a decline of approximately twenty five% year over year in U.S. sales reflecting ongoing headwinds that management acknowledged but did not fully explain. The downward trend raises concerns about the durability of the hybrid AF therapy approach in a market where patients and physicians are increasingly adopting pulsed field ablation catheters as a first line option. Without a clear strategy to reverse the decline the franchise could continue to erode contributing less to overall revenue and potentially weighing on total profitability. Management’s commitment to hybrid therapy appears to be more aspirational than tactical given the lack of detail on upcoming product enhancements or clinical data that would reinvigorate adoption.
International results were tempered by persistent uncertainty in the United Kingdom and lower distributor sales in Asia Pacific which management characterized as transient but offered no concrete timeline for improvement. The reliance on distributor channels in Asia exposes the company to order lumpiness and potential delays in revenue recognition that could cause quarterly volatility. Meanwhile the United Kingdom market faces systemic pressures such as budget constraints and shifting procurement practices that may not resolve quickly. If these headwinds prove more durable than anticipated the international growth rate could fall short of the low double digit target constraining overall top line expansion.
Competitive pressure in the left atrial appendage management space is intensifying with Medtronic already offering a competing product and Edwards signalling a planned entry later this year. Although AtriCure cites its clinical evidence advantage the ability of larger competitors to leverage expansive sales forces and established relationships could erode market share especially if pricing pressure increases. The company’s current ASP range from one thousand one hundred to two thousand two hundred fifty provides some flexibility but a sustained shift toward lower cost alternatives could compress margins. The lack of disclosed specifics on how AtriCure intends to defend its position beyond innovation leaves investors with uncertainty about the durability of its leadership.
The anticipated catalysts from the BoxX NoAF and LeAAPS trials are contingent on positive clinical outcomes and successful regulatory clearance both of which remain uncertain until the trials complete enrollment and follow up. Management’s discussion of the BoxX NoAF trial avoided disclosing any blinded data and offered only anecdotal observations from outside the trial creating a gap between expectation and verifiable evidence. Should the trials fail to demonstrate a statistically significant benefit in stroke reduction or postoperative atrial fibrillation prevention the premium valuation predicated on these breakthroughs could be quickly reassessed. Additionally the timeline for data readout and potential publication at major conferences remains vague with management suggesting a possible late breaker at a surgical congress rather than a guaranteed presentation.
Gross margin expansion in the first quarter was driven by an exceptionally favorable product and geographic mix that may not be sustainable as the company brings expanded manufacturing facilities online in the second half of the year. The increase in manufacturing cost burden associated with the new facilities is expected to moderate the full year gross margin outlook offsetting some of the gains achieved from mix benefits. Any unexpected rise in raw material costs or labor inflation could further pressure profitability especially as operating expenses continue to climb due to higher research and development spending tied to the accelerated BoxX NoAF trial. The current adjusted EBITDA guidance of eighty to eighty two million assumes that operating leverage will absorb these cost increases but there is limited visibility on the extent to which leverage will materialize.

The minimally invasive ablation franchise showed a decline of approximately twenty five% year over year in U.S. sales reflecting ongoing headwinds that management acknowledged but did not fully explain. The downward trend raises concerns about the durability of the hybrid AF therapy approach in a market where patients and physicians are increasingly adopting pulsed field ablation catheters as a first line option. Without a clear strategy to reverse the decline the franchise could continue to erode contributing less to overall revenue and potentially weighing on total profitability. Management’s commitment to hybrid therapy appears to be more aspirational than tactical given the lack of detail on upcoming product enhancements or clinical data that would reinvigorate adoption.
International results were tempered by persistent uncertainty in the United Kingdom and lower distributor sales in Asia Pacific which management characterized as transient but offered no concrete timeline for improvement. The reliance on distributor channels in Asia exposes the company to order lumpiness and potential delays in revenue recognition that could cause quarterly volatility. Meanwhile the United Kingdom market faces systemic pressures such as budget constraints and shifting procurement practices that may not resolve quickly. If these headwinds prove more durable than anticipated the international growth rate could fall short of the low double digit target constraining overall top line expansion.
Competitive pressure in the left atrial appendage management space is intensifying with Medtronic already offering a competing product and Edwards signalling a planned entry later this year. Although AtriCure cites its clinical evidence advantage the ability of larger competitors to leverage expansive sales forces and established relationships could erode market share especially if pricing pressure increases. The company’s current ASP range from one thousand one hundred to two thousand two hundred fifty provides some flexibility but a sustained shift toward lower cost alternatives could compress margins. The lack of disclosed specifics on how AtriCure intends to defend its position beyond innovation leaves investors with uncertainty about the durability of its leadership.
The anticipated catalysts from the BoxX NoAF and LeAAPS trials are contingent on positive clinical outcomes and successful regulatory clearance both of which remain uncertain until the trials complete enrollment and follow up. Management’s discussion of the BoxX NoAF trial avoided disclosing any blinded data and offered only anecdotal observations from outside the trial creating a gap between expectation and verifiable evidence. Should the trials fail to demonstrate a statistically significant benefit in stroke reduction or postoperative atrial fibrillation prevention the premium valuation predicated on these breakthroughs could be quickly reassessed. Additionally the timeline for data readout and potential publication at major conferences remains vague with management suggesting a possible late breaker at a surgical congress rather than a guaranteed presentation.
Gross margin expansion in the first quarter was driven by an exceptionally favorable product and geographic mix that may not be sustainable as the company brings expanded manufacturing facilities online in the second half of the year. The increase in manufacturing cost burden associated with the new facilities is expected to moderate the full year gross margin outlook offsetting some of the gains achieved from mix benefits. Any unexpected rise in raw material costs or labor inflation could further pressure profitability especially as operating expenses continue to climb due to higher research and development spending tied to the accelerated BoxX NoAF trial. The current adjusted EBITDA guidance of eighty to eighty two million assumes that operating leverage will absorb these cost increases but there is limited visibility on the extent to which leverage will materialize.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password